ÂÜÀòÂÒÂ×

Kathy Phlegar is a seasoned executive with extensive experience in the biotechnology and consulting industries. As Chief Executive Officer of GlycoPath Inc from February 2023 to May 2024, Kathy has demonstrated strong leadership. Previously, Kathy founded and led Phlegar & Associates from April 1995 to February 2023, focusing on cultivating client-consultant relationships. Participation on boards, including Blinktbi, Inc, and SCBIO, reflects Kathy's commitment to the biotech sector. Additional roles include U.S. Director of Business Development and Marketing at SOMATEX® Medical Technologies and Investment Officer at Westlake Partners. Prior experience includes a pivotal marketing director role at Hill Rom, managing a significant brand, and an early career internship at Arthur Andersen & Co. Kathy holds a Bachelor of Science from Clemson University and an MBA with a marketing concentration from the University of Florida.